Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › ASND

SILVERARC CAPITAL MANAGEMENT, LLC position in ASND

ASCENDIS PHARMA A/S · Health Care

SILVERARC CAPITAL MANAGEMENT, LLC reported holding 152,175 shares of ASND (ASCENDIS PHARMA A/S) in its Q3 2026 13F filing — a position valued at US$34.7M, representing 4.42% of its reported portfolio and ranking #7 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed ASND holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

Latest position (Q3 2026)152.18K sh
Reported value held$34.67M
Portfolio Weight4.42%
First reportedQ3 2024
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How SILVERARC CAPITAL MANAGEMENT, LLC's ASND position evolved

SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in ASND in Q3 2024 at 5,000 shares (US$747K). The position peaked in Q2 2026 at 206,234 shares, worth US$55.0M. Across 9 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 152,175 shares valued at US$34.7M — a reduction of -54,059 shares quarter over quarter.. Notable position changes include a 930% increase in Q4 2024 (shares rose 13% over the following quarter), a 153% increase in Q1 2026 (shares rose 17% over the following quarter), a 65% increase in Q2 2026 (shares fell 15% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 5.00K $746.55K New
Q4 2024 51.49K $7.09M Add
Q1 2025 75.75K $11.81M Add
Q2 2025 86.55K $14.94M Add
Q3 2025 53.55K $10.65M Reduce
Q4 2025 49.23K $10.50M Reduce
Q1 2026 124.66K $28.51M Add
Q2 2026 206.23K $55.01M Add
Q3 2026 152.18K $34.67M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ASND and 13F data

ASND (ASCENDIS PHARMA A/S) is a Health Care company. 37 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), Avoro Capital Advisors LLC (US$1.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ASND

All ASND fund holders →

FAQ

How long has SILVERARC CAPITAL MANAGEMENT, LLC held ASND?

SILVERARC CAPITAL MANAGEMENT, LLC has disclosed ASND holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in ASND?

As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 152.18K shares of ASND (ASCENDIS PHARMA A/S), valued at $34.67M, representing 4.42% of its reported portfolio and ranking #7.

Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling ASND?

In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC reduced its position in ASND. The position peaked in Q2 2026 at 206.23K shares.

Which other funds hold ASND?

Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.